Until now, no technology has been capable of substantially reducing all types of pathogens in biological products in their final packaging, while maintaining the integrity of the underlying protein in the product. Various current sterilization and cleansing methods exist but they cannot sterilize in their final packaging or can only destroy limited or specific types of pathogens (such as bacteria or lipid enveloped viruses) in specific types of products. The Clearant Process® substantially inactivates all types of known pathogens for products across a variety of market segments including plasma therapies, tissue allograft implants, recombinant products and blood products. In addition, Clearant achieves this sterilization in its final packaging.
IP: Logged |
There is a 100 person increase in their sales force because of demand. The CEO clearly stated that he wants to UPLIST and he also said that he will be doing PR's in the very near future.
From Google on CLRA
Clearant, Inc. acquires and develops pathogen inactivation technology, the Clearant Process, and markets it to producers of biological products. The Clearant Process technology inactivates pathogens that may contaminate biological products, such as tissue allograft implants, recombinant protein therapeutics, plasma protein therapeutics, blood and blood-related products. The Clearant Process enables customers to meet the medical need for safer biological products and to satisfy current and future product safety guidelines. The Company’s primary business model is to distribute Clearant Process tissue to surgeons, hospitals and surgery centers
IP: Logged |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): November 19, 2009
Clearant, Inc.
__________________________________________ (Exact name of registrant as specified in its charter)
Delaware 000-50309 912190195 _____________________ (State or other jurisdiction _____________ (Commission ______________ (I.R.S. Employer of incorporation) File Number) Identification No.)
1801 Avenue of the Stars, Suite 435, Los Angeles, California 90067 _________________________________ (Address of principal executive offices) ___________ (Zip Code)
Registrant’s telephone number, including area code: (310) 479-4570 Not Applicable ______________________________________________ Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) [ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) [ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) [ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Top of the Form Item 7.01 Regulation FD Disclosure.
Clearant has begun exploring possible regulatory and legislative lobbying efforts to increase the standard of care to a sterility assurance level of 10-6 for muskuloskeletal allografts. Clearant is one of the only commercially available processes proven to achieve a terminal sterility assurance level of 10-6.
Unless otherwise required by law, we disclaim any obligations to release publicly any updates or changes in our expectations or any change in events, conditions, or circumstances on which any forward-looking statements are based.
Top of the Form SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Clearant, Inc.
November 19, 2009 By: /s/ Jon Garfield
Name: Jon Garfield Title: Chief Executive Officer
IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
